Last reviewed · How we verify

NCT04761328

Fear of Recurrence and Stopping Immunotherapy

Recruiting now NA Last updated 5 December 2025
What this trial tests

NA trial testing cognitive behavioral therapy in Cognitive Behavioral Therapy in 100 participants. Currently enrolling.

Timeline
2 August 2021
Primary endpoint
31 December 2027
31 December 2028

Quick facts

Lead sponsorUniversity of Pittsburgh
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment100
Start date2 August 2021
Primary completion31 December 2027
Estimated completion31 December 2028
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Pittsburgh

Who can join

21 and older, any sex, with Cognitive Behavioral Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study includes participants experiencing distress with regard to stopping immunotherapy and will utilize cognitive-behavioral therapy to reduce fear of recurrence, depression, and anxiety and improve quality of life.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of cognitive behavioral therapy

Trials testing the same drug.

Other recruiting trials for Cognitive Behavioral Therapy

Currently open trials in the same condition.

Other University of Pittsburgh trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04761328.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing